Childhood leukemia blood test results usually show a combination of abnormalities rather than one decisive number: anemia, thrombocytopenia, and a white cell count that may be high, normal, or low, often with blasts on the peripheral smear. No single blood test confirms the diagnosis. The complete blood count (CBC) and film raise suspicion, and bone marrow examination with flow cytometry and genetic testing confirms it and sets the risk group.
This guide is written for clinicians who order and interpret these tests, though parents will find the explanations useful too. It builds on our broader article on leukemia blood test results and focuses on what is different in children.
Childhood Leukemia at a Glance
Leukemia is the most common cancer of childhood. It arises in the bone marrow, where a clone of immature cells multiplies and crowds out normal blood production. Almost all pediatric cases are acute.
- Acute lymphoblastic leukemia (ALL) accounts for the large majority of cases, with a peak incidence between roughly ages 2 and 5.
- Acute myeloid leukemia (AML) is less common in children and is seen across all ages, including infancy.
- Chronic myeloid leukemia and juvenile myelomonocytic leukemia are rare.
Our overviews of the different types of childhood leukemia and managing childhood leukemia cover these subtypes in more detail. Known risk factors include Down syndrome, certain inherited cancer predisposition syndromes, and prior exposure to ionizing radiation or chemotherapy, but most children have no identifiable cause.
Initial Blood Tests: CBC, Chemistry, and Coagulation
The CBC is usually the first test that points toward leukemia. The key interpretive step is to read every cell line together and against age-specific reference ranges, since normal pediatric values differ from adult values and change through infancy and childhood.
| Parameter | Typical finding in acute leukemia | Clinical significance |
|---|---|---|
| Hemoglobin | Low, often normocytic with low reticulocytes | Marrow failure rather than blood loss or hemolysis |
| Platelets | Low, sometimes markedly | Explains bruising, petechiae, and mucosal bleeding |
| White cell count | High, normal, or low | A normal WBC does not exclude leukemia |
| Absolute neutrophil count | Often low | Infection risk; below 0.5 × 10⁹/L is severe neutropenia |
| Blood film | Circulating blasts in many, not all, cases | Most specific early clue; absence does not rule out disease |
Bicytopenia or pancytopenia in a child with fever, pallor, bone pain, or organomegaly should prompt urgent review of the film by an experienced hematologist. Isolated mild cytopenia after a viral illness is far more common and usually resolves, but persistent or progressive changes need investigation.
Why a normal white count can mislead
Many children with ALL present with a normal or low white count, sometimes called “aleukemic” presentation. In these cases the blasts are confined to the marrow. The clues are anemia and thrombocytopenia together, low red blood cell production, and the clinical picture. Distinguishing leukemic cells from reactive lymphocytes requires comparing white and red blood cells on the film with care.
Hyperleukocytosis
A white count above 100 × 10⁹/L is termed hyperleukocytosis. It raises the risk of leukostasis, tumor lysis syndrome, and bleeding, and it is a medical emergency requiring hydration, close monitoring, and prompt specialist care.
Chemistry and coagulation tests
Beyond the CBC, a baseline biochemistry panel is essential at presentation because a high tumor burden can cause dangerous metabolic changes.
- Lactate dehydrogenase (LDH) and uric acid: often raised, reflecting high cell turnover.
- Potassium and phosphate: rising levels, with falling calcium, suggest tumor lysis syndrome.
- Creatinine: monitors kidney function before and during treatment.
- Coagulation screen (PT, APTT, fibrinogen, D-dimer): disseminated intravascular coagulation is classically associated with acute promyelocytic leukemia but can occur in other subtypes.
These tests shape the first 48 hours of management as much as the diagnosis itself. They also help distinguish leukemia from other abnormal blood conditions that can present with similar counts.
Confirming the Diagnosis
Peripheral blood findings must be confirmed with a bone marrow aspirate and trephine biopsy. In children this is usually done under sedation or general anesthesia. The marrow sample undergoes several parallel analyses.
- Morphology: blast percentage and appearance. A blast count of 20% or more is the classic diagnostic threshold for acute leukemia, with some pediatric protocols using a higher cut-off for ALL.
- Flow cytometry (immunophenotyping): identifies lineage (B-cell, T-cell, or myeloid) from surface and cytoplasmic markers.
- Cytogenetics and FISH: detect chromosome changes such as hyperdiploidy, ETV6-RUNX1, the Philadelphia chromosome (BCR-ABL1 from t(9;22)), and KMT2A rearrangements.
- Molecular testing: next-generation sequencing identifies mutations that inform risk and targeted therapy.
A lumbar puncture with cerebrospinal fluid cytology assesses central nervous system involvement, which affects treatment intensity. Understanding normal blood cell development helps explain why the stage at which maturation arrests determines the leukemia subtype.
Using Results for Risk Stratification
Initial results do more than confirm leukemia; they assign a risk group that guides therapy intensity. For B-cell ALL, widely used criteria consider age and presenting white count, with children aged 1 to under 10 years and a WBC below 50 × 10⁹/L generally placed in the more favorable group.
Genetics refine this further. Hyperdiploidy and ETV6-RUNX1 are associated with a favorable outlook, while KMT2A rearrangements (common in infant ALL), hypodiploidy, and Philadelphia-positive disease carry higher risk. The most powerful predictor, however, is response to treatment.
Minimal residual disease
Minimal residual disease (MRD) testing uses flow cytometry or molecular methods to detect leukemic cells far below what microscopy can see. MRD at the end of induction therapy is central to modern pediatric protocols; a commonly used threshold is 0.01% (one leukemic cell in 10,000). Children who remain MRD-positive typically receive intensified therapy.
Monitoring Blood Tests During Treatment
Once treatment begins, blood tests shift from diagnosis to safety and response monitoring. Frequent CBCs track marrow recovery and neutropenia, guiding decisions on transfusion and infection precautions. Liver function, glucose, amylase, and coagulation are checked for drug toxicities such as asparaginase-related effects. Thiopurine metabolite and TPMT or NUDT15 testing can guide dosing of maintenance chemotherapy.
Treatment usually combines multi-agent chemotherapy, with stem cell transplantation, CAR T-cell therapy, bispecific antibodies, or tyrosine kinase inhibitors used for selected high-risk or relapsed disease. Our section on hematological disorders places these therapies in wider context, and the leukemia guide covers each in turn.
When to See a Doctor or Refer Urgently
Clinicians should arrange same-day pediatric hematology or oncology review when a child has:
- Blasts reported on a blood film.
- Two or more unexplained cytopenias, or pancytopenia.
- Very high white count, or any count abnormality with hepatosplenomegaly or lymphadenopathy.
- Unexplained petechiae, bruising, or bleeding with pallor or bone pain.
For families, the practical point is simple: persistent tiredness, pallor, unexplained bruises, or ongoing bone pain in a child deserve a blood test rather than waiting. You can also read our patient-facing article on the blood test for leukemia.
Frequently Asked Questions
Can a routine CBC miss childhood leukemia?
Yes, early in the disease the CBC can be near normal or show only mild changes. Repeat testing is appropriate when symptoms persist, and a bone marrow examination is needed when suspicion remains high.
Do blasts on a blood film always mean leukemia?
Not always. Occasional immature cells can appear in severe infection or marrow recovery, and reactive lymphocytes can resemble blasts. Flow cytometry of blood or marrow resolves the question.
What blood test results suggest a good prognosis?
In B-cell ALL, age between 1 and 10 years, a lower presenting white count, favorable genetics such as hyperdiploidy or ETV6-RUNX1, and MRD negativity after induction are all associated with better outcomes.
How often are blood tests done during treatment?
Frequently during intensive phases, often several times a week, and less often during maintenance. The schedule depends on the protocol and the child’s counts.
